US Restrictions On HMOs Shelved Temporarily

14 July 1996

In the USA, the Clinton Administration has temporarily shelved new rules that would have restricted health maintenance organizations from rewarding doctors who cut costs and control use of services by Medicare and Medicaid patients, according to a New York Times report.

The rules, mandated by a 1990 law, were issued at the end of March to protect consumers by limiting the use of these financial incentives. They were supposed to take effect on May 28, but the Clinton Administration has pulled them back for further review, without any notice to consumers. In a memorandum to HMOs dated May 28, the Administration said it realized the compliance date is unrealistic. The memo, the NYT noted, added that the government would not take any enforcement action before January 1, 1997.

Protests from HMOs forced the Department of Health and Human Services to suspend enforcement of the rule, said the NYT, which noted that the companies said the rules would force them to rewrite contracts with many doctors. The HMOs also accused the government of not understanding the importance of financial incentives in a fast-growing, highly competitive industry.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight